Matching articles for "fam-trastuzumab deruxtecan"
In Brief: An Expanded Indication for Enhertu
The Medical Letter on Drugs and Therapeutics • May 25, 2026; (Issue 1755)
Fam-trastuzumab deruxtecan (Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in
combination with pertuzumab (Perjeta) for first-line treatment
of HER2-positive unresectable or...
Fam-trastuzumab deruxtecan (Enhertu – Daiichi Sankyo/AstraZeneca) has now been approved by the FDA for use in
combination with pertuzumab (Perjeta) for first-line treatment
of HER2-positive unresectable or metastatic breast cancer.
The drug was approved earlier for use as monotherapy in
adults with previously treated HER2-positive unresectable or
metastatic breast cancer.
Two Drugs for Advanced HER2-Positive Breast Cancer (Enhertu and Tukysa)
The Medical Letter on Drugs and Therapeutics • November 16, 2020; (Issue 1611)
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab...
The FDA has approved two new drugs for treatment
of previously-treated unresectable or metastatic
human epidermal growth factor receptor 2 (HER2)-positive breast cancer: fam-trastuzumab deruxtecannxki
(Enhertu – Daiichi-Sankyo/AstraZeneca), an IV
HER2-directed monoclonal antibody linked to the
topoisomerase I inhibitor DXd, and tucatinib (Tukysa – Seagen), an oral tyrosine kinase inhibitor.